490030-45-0

Usage

Molecular weight

369.36 g/mol

Structure

An ester derivative of piperazinecarboxylic acid, containing a tert-butyl group and a trifluoromethoxyphenyl group.

Biological activity

Potential for biological activity due to its structure and functional groups.

Applications

Potential applications in pharmaceuticals and research, including the development of new drugs or as a research tool in the study of molecular interactions.

Further investigation needed

Additional research and testing is required to fully understand the properties and potential uses of 1-Piperazinecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester.

Upstream product

• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 76144-87-1 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl 

Downstream Products

• 187669-62-1 1-(4-(trifluoromethoxy)phenyl)piperazine 
• 1426520-98-0 C₁₈H₂₀F₃N₃O 
• 1613627-52-3 C₁₈H₁₆F₃N₃O 
• 490030-46-1 1-(4-(trifluoromethoxy)phenyl)piperazine hydrochloride 

Relevant academic research and scientific papers

NOVEL VDAC1 INHIBITORS

The present invention relates to a compound of general formula I Wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula I binds to VDAC1 and is suitable for use in a method for treating diabetes or pre-diabetes in a subject

Nitroimidazole compound as well as preparation method and application thereof

The invention discloses a novel nitroimidazole compound as well as a preparation method and application thereof. The nitroimidazole compound has a general formula (I) shown in the specification.

Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors

The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.

5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION

Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's disease.

ANTI-INFECTIVE COMPOUNDS

The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES

A compound of formula (I) wherein the substituents are described in claim 1 for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.